Category: Metabolic Research | Reading time: 6 min | For research use only
Retatrutide (LY3437943) is an investigational synthetic peptide developed by Eli Lilly and Company that acts simultaneously on three incretin and metabolic hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple agonist mechanism — sometimes called a "triagonist" or "triple incretin" — distinguishes Retatrutide from approved GLP-1 monotherapy agents (semaglutide) and dual GLP-1/GIP agonists (tirzepatide), and has positioned it as one of the most discussed investigational metabolic peptides of 2025–2026.
This article summarizes published research on Retatrutide for scientific and educational purposes. All compounds discussed are strictly for laboratory and research use only.
Molecular Profile
- INN / Development code: Retatrutide / LY3437943
- Class: Triple GLP-1/GIP/glucagon receptor agonist (triagonist)
- Molecular weight: ~4,900 g/mol (approximate; full sequence proprietary)
- Structure: Acylated peptide with C20 fatty diacid moiety for albumin binding (similar structural strategy to tirzepatide)
- Half-life: ~6 days (enabling once-weekly administration in clinical trials)
- Administration route: Subcutaneous injection in clinical trials
- Development status: Phase 3 clinical trials as of 2026
- Form (research): Lyophilized powder (research grade)
Retatrutide's three-receptor targeting strategy reflects a deliberate mechanistic design: GLP-1 and GIP agonism address insulin secretion and appetite regulation, while glucagon receptor agonism adds a distinct metabolic lever — increased hepatic glucose output and energy expenditure — that is absent in dual-agonist compounds.
Receptor Mechanisms
GLP-1 Receptor Agonism
GLP-1 receptors are expressed in pancreatic beta cells, the central nervous system, and gastrointestinal tissue. Activation produces glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite regulation via hypothalamic signaling. This mechanism is shared with semaglutide and tirzepatide.
GIP Receptor Agonism
GIP receptors are expressed in pancreatic tissue, adipose tissue, bone, and the CNS. GIP receptor activation contributes to insulin secretion synergistically with GLP-1 and has been associated with differential effects on adipose tissue lipid metabolism. This mechanism is shared with tirzepatide.
Glucagon Receptor Agonism — The Novel Addition
Glucagon receptors are expressed primarily in the liver, kidney, and adipose tissue. Glucagon is classically understood as a counter-regulatory hormone — it raises blood glucose by stimulating hepatic glycogenolysis and gluconeogenesis. This apparently paradoxical mechanism in a metabolic compound requires explanation:
At the doses studied in Retatrutide research, the glucagon receptor agonism is designed to produce:
- Increased hepatic lipid oxidation — glucagon receptor activation promotes fat burning in liver tissue, which may contribute to reduction in hepatic steatosis (liver fat)
- Increased energy expenditure — glucagon has thermogenic effects through brown adipose tissue activation
- Appetite modulation — central glucagon receptor signaling contributes to satiety independently of GLP-1 pathways
The GLP-1 component simultaneously suppresses the hyperglycemic effects of glucagon receptor activation, creating a theoretically complementary balance: the metabolic and thermogenic benefits of glucagon signaling without net hyperglycemia.
Clinical Research Findings
Retatrutide has the most extensive published weight loss data of any investigational peptide as of 2026.
SURMOUNT-Adjacent Phase 2 Data (Jastreboff et al., NEJM 2023)
The landmark Phase 2 trial of Retatrutide published in the New England Journal of Medicine reported:
- Mean body weight reduction of 24.2% at the highest dose (12mg) over 48 weeks — the largest weight reduction ever reported in a randomized controlled trial of any pharmacological intervention at that point
- Dose-dependent effects with 8mg showing approximately 22.8% reduction
- Continuous weight loss trajectory at 48 weeks with no clear plateau, suggesting further reduction with extended treatment
- Improvements in waist circumference, blood pressure, lipid profiles, and glycemic markers
For comparison, tirzepatide (15mg) showed approximately 20.9% body weight reduction in the SURMOUNT-1 trial over 72 weeks. Retatrutide's Phase 2 data at 48 weeks exceeded this, generating significant scientific interest in the incremental contribution of glucagon receptor agonism.
Metabolic Parameter Research
Beyond body weight, published Phase 2 data documented:
- HbA1c reductions in participants with type 2 diabetes
- Significant reductions in liver fat fraction (measured by MRI) — a finding attributed partly to the glucagon receptor mechanism
- Favorable effects on triglycerides and LDL cholesterol
- Improvements in blood pressure independent of weight loss contribution
Tolerability Profile
Published data reports a tolerability profile broadly similar to other GLP-1-class peptides, with nausea, vomiting, and gastrointestinal effects as the most common adverse events, predominantly during dose escalation phases. Heart rate increases were observed, consistent with GLP-1/glucagon receptor class effects. Phase 3 trials include dedicated cardiovascular outcomes assessment.
Retatrutide vs Tirzepatide vs Semaglutide: Research Comparison
| Parameter | Semaglutide 2.4mg | Tirzepatide 15mg | Retatrutide 12mg |
|---|---|---|---|
| Receptor targets | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Trial weight loss | ~14.9% (68 wks) | ~20.9% (72 wks) | ~24.2% (48 wks) |
| Trial program | STEP | SURPASS/SURMOUNT | Phase 2 (Phase 3 ongoing) |
| Half-life | ~7 days | ~5 days | ~6 days |
| Liver fat reduction | Moderate | Moderate-significant | Significant (glucagon mechanism) |
| Approval status | FDA-approved | FDA-approved | Phase 3 trials |
Note: Cross-trial comparisons require caution — different study designs, populations, durations, and endpoints make direct numerical comparisons imprecise. These figures are provided for research context only.
Ongoing Research Areas
Phase 3 Clinical Program Retatrutide is currently in Phase 3 trials examining long-term weight loss maintenance, cardiovascular outcomes, and effects in populations with obesity-related comorbidities including type 2 diabetes, heart failure, and non-alcoholic steatohepatitis (NASH/MAFLD).
Liver disease research The glucagon receptor component's documented association with hepatic lipid reduction has generated specific research interest in NASH/MAFLD models. Dedicated liver disease trials are examining whether Retatrutide's triple mechanism confers advantage over dual agonists in this context.
Muscle composition research A research question with Retatrutide — as with all significant weight loss interventions — is the proportion of lean mass versus fat mass loss. Glucagon receptor agonism's potential to preferentially mobilize fat while sparing lean mass is being investigated in body composition sub-studies.
Combination and comparative models Preclinical research using Retatrutide alongside other compounds is examining synergistic pathways and complementary mechanisms, particularly in models examining the relative contributions of each receptor to the overall metabolic phenotype.
Key Published Research
- Jastreboff AM, et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389, 514–526.
- Coskun T, et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234–1247.
- Rosenstock J, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet, 402(10401), 529–544.
Research Considerations
Retatrutide remains an investigational compound without regulatory approval as of 2026. All published efficacy and safety data derives from Phase 2 clinical trials; Phase 3 data continues to emerge. Researchers should consult current trial registries (ClinicalTrials.gov, EU Clinical Trials Register) for the most recent published and registered findings.
The glucagon receptor component introduces pharmacological complexity not present in GLP-1 monotherapy or dual agonist compounds. Researchers designing in vitro or animal model studies with Retatrutide should account for all three receptor interactions in experimental design and data interpretation.
NordBioLab supplies Retatrutide as a research-grade lyophilized peptide with ≥98% purity (HPLC verified) and full COA documentation per batch.
View Retatrutide in our catalog →
All products and information provided by NordBioLab are strictly for scientific research and laboratory use only. Not for human or veterinary consumption. This article does not constitute medical advice.